Hip fractures following denosumab discontinuation: three clinical cases reports

Manuel Sosa Henríquez; María Jesús Gómez de Tejada Romero; María Escudero-Socorro; Oscar Torregrosa Suau

doi:10.1177/0141076819861027

Hip fractures following denosumab discontinuation: three clinical cases reports

J R Soc Med. 2019 Nov;112(11):472-475. doi: 10.1177/0141076819861027. Epub 2019 Sep 17.

Authors

Manuel Sosa Henríquez^{1

2}, María Jesús Gómez de Tejada Romero³, María Escudero-Socorro⁴, Oscar Torregrosa Suau⁵

Affiliations

¹ Department of Medical and Surgical Sciences, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, 35016 Spain.
² Bone Metabolic Unit, Insular University Hospital, Las Palmas de Gran Canaria, 35016 Spain.
³ Department of Medicine, University of Seville, Seville, 41009 Spain.
⁴ Rehabilitation Service, Dr. Negrín University Hospital, Las Palmas de Gran Canaria, 35010 Spain.
⁵ Service of Internal Medicine, General University Hospital, Elche, 03203 Spain.

Abstract

A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.

Keywords: Denosumab; discontinuation; fracture; hip.

Publication types

Case Reports

MeSH terms

Absorptiometry, Photon
Aged
Aged, 80 and over
Bone Density / drug effects*
Bone Density Conservation Agents / pharmacology
Denosumab / pharmacology*
Female
Hip Fractures / diagnosis
Hip Fractures / etiology*
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*
Withholding Treatment*

Substances

Bone Density Conservation Agents
Denosumab